Masakazu Takeuchi
Kobe, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 27 publications
Long-term safety of oral orforglipron in Japanese participants with type 2 diabetes (ACHIEVE-J): a multicentre, randomised, open-label, parallel-group phase 3 trial.
Journal: The lancet. Diabetes & endocrinology
Published: January 22, 2026
Decreased fatty liver index with tirzepatide treatment in Japanese patients with type 2 diabetes: A SURPASS J-mono post hoc analysis.
Journal: Diabetes, obesity & metabolism
Published: August 11, 2025
Correction to: The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: February 07, 2025
The Long-Term Cost-Effectiveness of Tirzepatide 5 mg versus Dulaglutide 0.75 mg for the Treatment of People with Type 2 Diabetes in Japan.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 02, 2024
Association of bodyweight loss with changes in lipids, blood pressure, and fasting serum glucose following tirzepatide treatment in Japanese participants with type 2 diabetes: A post hoc analysis of the SURPASS J-mono trial.
Journal: Journal of diabetes investigation
Published: July 28, 2024
Achieving normoglycaemia with tirzepatide: Post hoc exploratory analysis of the SURPASS J-mono and J-combo studies.
Journal: Diabetes, obesity & metabolism
Published: April 04, 2024
A randomized, double-blind trial assessing the efficacy and safety of two doses of dulaglutide in Japanese participants with type 2 diabetes (AWARD-JPN).
Journal: Diabetes, obesity & metabolism
Published: January 23, 2024
Metabolic Abnormalities Following Tirzepatide Monotherapy in Japanese Patients with Type 2 Diabetes: A Phase 3 SURPASS J-mono Post Hoc Analysis.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: October 29, 2023
Treatment Satisfaction and Quality of Life with Tirzepatide Versus Dulaglutide Among Japanese Patients with Type 2 Diabetes: Exploratory Evaluation of the SURPASS J-mono Trial.
Journal: Diabetes therapy : research, treatment and education of diabetes and related disorders
Published: August 03, 2023
Glucose-dependent insulinotropic polypeptide counteracts diet-induced obesity along with reduced feeding, elevated plasma leptin and activation of leptin-responsive and proopiomelanocortin neurons in the arcuate nucleus.
Journal: Diabetes, obesity & metabolism
Published: September 27, 2022
Changes in prescription patterns and doses of oral antidiabetic drugs in Japanese patients with type 2 diabetes (JDDM70).
Journal: Journal of diabetes investigation
Published: July 14, 2022
Change in pharmacodynamic variables following once-weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes (SURPASS J-mono substudy).
Journal: Diabetes, obesity & metabolism
Published: July 12, 2022
Last Updated: 09/26/2026